Xeris Pharmaceuticals Reports Q3 Earnings Beat and Increases Full-Year Revenue Guidance
Xeris Pharmaceuticals (XERS) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a GAAP earnings per share (EPS) of $0.06, surpassing estimates by $0.07, while total revenue reached $107.2 million, representing a 44.1% increase year-over-year. A significant driver of this growth was the Recorlev product line, which saw net revenue surge by 93% year-over-year to over $71 million. Following these strong results, Xeris Pharmaceuticals has raised its full-year 2026 total revenue guidance to $395 million, signaling confidence in continued commercial momentum.
